Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Janssen JC, van Dijk B, de Joode K, Aarts MJB, et al. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol. BMC Cancer 2024;24:632.
PMID: 38783238


Privacy Policy